financetom
Business
financetom
/
Business
/
EbixCash signs strategic partnership agreement with MoneyGram
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EbixCash signs strategic partnership agreement with MoneyGram
Jan 13, 2020 8:00 AM

EbixCash, a fully owned subsidiary of Ebix has signed an agreement with global money transfer and payment services player, MoneyGram to expand presence in India. Through this agreement, EbixCash will be MoneyGram’s exclusive partner in India. The aim of this partnership is to bring inward remittance volumes of 3 billion dollars annually.

“EbixCash will be MoneyGram’s exclusive partner in India. We see this as a very lucrative and high margin intensive deal. MoneyGram will be handling the inward remittances and EbixCash will be doing the servicing job,” said Robin Raina, Chairman, Ebix, without disclosing the commission structure.

The deal will allow MoneyGram to be able to reach additional consumers through Ebix’s 320,000 distribution outlets spread across 768 districts, 4,000 cities, and more than 75,000 villages and this will significantly increase its coverage in rural areas.

Through this partnership, EbixCash is expecting to clock net revenues between $20-$35 million annually. “This is a very conservative estimate. We expect to scale up revenues further and could look at annual revenues of about $50m over the next 2-3 years via this partnership,” said Raina.

Last week, the BSE-Ebix joint venture received formal approval for Certificate of Registration to act as a direct insurance broker (Life and General) under the IRDAI (Insurers Brokers) Regulations, 2018.

“We intend to do a soft launch in the second week of February for the insurance business. We are also planning to launch India's first re-insurance exchange in 2020,” shared Raina.

It's noteworthy that EbixCash has plans of going public. The company has already appointed bankers to the issue and is working with a July-August timeframe for the IPO.

First Published:Jan 13, 2020 5:00 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
EU looks to Big Tech, influencers to fight hybrid threats, fake news
EU looks to Big Tech, influencers to fight hybrid threats, fake news
Nov 12, 2025
BRUSSELS (Reuters) -Europe is looking to online platforms and influencers to help fight disinformation and promote democracy according to a European Commission strategy presented on Wednesday amid concerns over interference by foreign governments in national elections. Alphabet's Google, Microsoft ( MSFT ), Meta Platforms, Elon Musk's X, TikTok and other online platforms already have to do more to tackle illegal...
Ad-tech platform Perion Q3 adjusted EPS beats estimates
Ad-tech platform Perion Q3 adjusted EPS beats estimates
Nov 12, 2025
Overview * Perion Q3 2025 revenue grows 8% yr/yr, driven by CTV and Digital out of home (DOOH) growth * Adjusted EPS for Q3 beats consensus, reflecting strong operational performance * Company expands share repurchase program to $200 mln, reflecting confidence in growth Outlook * Perion reiterates FY 2025 revenue guidance of $430 mln to $450 mln * Perion expects...
Innoviz Technologies' Q3 revenue beats on increase in LiDAR unit shipments
Innoviz Technologies' Q3 revenue beats on increase in LiDAR unit shipments
Nov 12, 2025
Overview * Innoviz Q3 2025 revenue grows to $15.3 mln, beating analyst expectations * Company selected for L4 autonomous truck series production by major OEM Outlook * Company reiterates FY 2025 revenue target of $50-$60 mln * Innoviz ( INVZ ) targets 1-3 new program wins in FY 2025 * Company expects FY 2025 NRE bookings of $30-$60 mln Result...
Prelude Therapeutics Q3 net loss narrows
Prelude Therapeutics Q3 net loss narrows
Nov 12, 2025
Overview * Prelude Q3 2025 net loss narrows to $19.7 mln from $32.3 mln year-over-year * Company reports cash runway into 2027 after receiving $60 mln from Incyte * Lead candidates from JAK2V617F and KAT6A programs advancing to clinical trials Outlook * Prelude anticipates filing IND for JAK2V617F inhibitor in first half of 2026 * Company expects cash runway to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved